KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Globus Medical (GMED) EBITDA Margin (2016 - 2025)

Globus Medical's EBITDA Margin history spans 15 years, with the latest figure at 17.55% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1350.0% year-over-year to 17.55%; the TTM value through Dec 2025 reached 19.06%, up 1484.0%, while the annual FY2025 figure was 19.06%, 1484.0% up from the prior year.
  • EBITDA Margin reached 17.55% in Q4 2025 per GMED's latest filing, up from 15.56% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 28.88% in Q2 2025 to a low of 1.31% in Q1 2024.
  • Average EBITDA Margin over 5 years is 13.05%, with a median of 15.76% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: skyrocketed 2556bps in 2021, then crashed -2095bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 4.55% in 2021, then surged by 361bps to 21.01% in 2022, then crashed by -82bps to 3.82% in 2023, then grew by 6bps to 4.05% in 2024, then soared by 333bps to 17.55% in 2025.
  • Per Business Quant, the three most recent readings for GMED's EBITDA Margin are 17.55% (Q4 2025), 15.56% (Q3 2025), and 28.88% (Q2 2025).